Agoraphobia

Introduction & Epidemiology - Crowd Fear Defined

• Definition: Marked fear/anxiety about ≥2 agoraphobic situations (e.g., public transport, open/enclosed spaces, crowds, outside home alone).
• Core Fear: Escape difficult or help unavailable if panic-like/incapacitating symptoms occur.
• Epidemiology:
  • Prevalence: ~1.7% (12-month).
  • Age of Onset: Late adolescence/early adulthood (mean ~20 yrs).
  • Gender: Females > Males (F:M ≈ 2:1).

⭐ Agoraphobia often develops as a complication of panic disorder.

Clinical Features & DSM-5 - Panic's Prison Walls

• Key Agoraphobic Situations (📌 Mnemonic: PLACES): Marked fear/anxiety about ≥2 of:
  • Public transport
  • Lines/Crowds
  • Away from home (being alone)
  • Closed spaces (e.g., shops, theatres)
  • Empty/Open spaces (e.g., parking lots, markets)
• Central Cognitive Theme: Thoughts that escape difficult/help unavailable if panic-like or other incapacitating/embarrassing symptoms (e.g., fear of falling, incontinence) occur.
• DSM-5 Essentials:
  • Situations actively avoided, require a companion, or endured with intense fear/anxiety.
  • Symptoms persist for ≥6 months.
  • Causes clinically significant distress or impairment (social, occupational).
  • ⭐

    The fear/anxiety is out of proportion to the actual danger posed by the agoraphobic situations and to the sociocultural context.

Differential Diagnosis & Comorbidity - What Else Lurks?

Key Differential Diagnoses:

• Other anxiety disorders (Panic Disorder, GAD)
• Depression (MDD)
• Substance Use Disorders (SUD)

⭐ Approximately 50% of individuals with agoraphobia also have a current panic disorder.

Management - Escape Route Plan

⭐

Exposure therapy is the most effective psychological treatment for agoraphobia.

• Core Approach: Combination of psychotherapy & pharmacotherapy often optimal.
• Psychotherapy (1st Line):
  • Cognitive Behavioral Therapy (CBT): Gold standard.
    • Exposure Therapy: Key component.
      • Principles: Gradual, systematic, prolonged, repeated confrontation with feared situations/sensations (in vivo > imaginal).
      • Develop an "exposure hierarchy".
      • Goal: Habituation, reduce avoidance.
• Pharmacotherapy:
  • First-line:
    • SSRIs: Sertraline (50-200 mg/day), Paroxetine (20-60 mg/day). Start low, titrate slowly.
    • SNRIs: Venlafaxine XR (75-225 mg/day).
  • Second-line / Adjunctive:
    • TCAs: (e.g., Imipramine) if SSRI/SNRI ineffective/contraindicated.
    • Benzodiazepines (BZDs): (e.g., Clonazepam 0.5-2 mg PRN) for short-term relief of severe anxiety; ⚠️ high dependence risk, avoid long-term monotherapy.

Prognosis & Course - Freedom's Forecast

• Course: Often chronic if untreated; symptoms wax & wane.
• Better Prognosis:
  • Early treatment.
  • No comorbid personality disorder.
  • Good social support.
  • Later age of onset.
• Worse Prognosis:
  • Comorbid depression/anxiety.
  • Severe panic symptoms & avoidance.
  • Early age of onset.
• Remission: ~50-60% with therapy (CBT) & SSRIs.
• QoL Impact: Severe if untreated; affects daily, social, work life.

⭐ Early treatment is associated with a better prognosis in agoraphobia.

High‑Yield Points - ⚡ Biggest Takeaways

• Agoraphobia: Marked fear/anxiety about ≥2 situations (e.g., public transport, open/enclosed spaces, crowds, outside home alone).
• Core fear: difficult escape or unavailable help if panic-like or incapacitating symptoms arise.
• Situations are actively avoided, require a companion, or are endured with intense fear.
• The fear/anxiety is out of proportion to the actual danger posed by the situations.
• Symptoms persist for ≥6 months and cause clinically significant distress or impairment.
• Treatment: SSRIs are first-line pharmacotherapy; Cognitive Behavioral Therapy (CBT), especially exposure therapy, is key psychotherapy.